Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 11/20 | 0.49 |
| ▸ | HTR2C | P28335 | 8/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12081257 | 0.87 | HTR2C (0.47) | HTR1AHTR2CSLC6A2SLC6A4SLC6A3 | |
| Methyl Alcohol SCHEMBL27462714 | 0.83 | HTR1A (0.54) | HTR1A | |
| Methylamine SCHEMBL27483381 | 0.83 | HTR1A (0.51) | ADRB1HTR1A | |
| SCHEMBL9934153 | 0.79 | HTR2C (0.46) | HTR2C | |
| SCHEMBL614437 | 0.79 | HTR1A (0.46) | HTR1AHTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9715368 | 0.78 | EED (0.51) | HTR1AHTR2C | |
| SCHEMBL27449991 | 0.78 | HTR2C (0.45) | HTR1AHTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL26005486 | 0.74 | HTR2C (0.45) | HTR1AHTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL26005718 | 0.74 | HTR2C (0.49) | HTR1AHTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16309063 | 0.74 | L3MBTL1 (0.47) | ADRB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| EP-0711291-B1 | N-(PIPERIDINYL-1-ALKYL)-SUBSTITUTED CYCLOHEXANE CARBOXYLIC ACID AMIDES AS 5-HT1A RECEPTOR ANTAGONISTS | WYETH JOHN & BROTHER LTD (GB) | 1998-11-25 | — | — | EP | disclosed |
| US-5763460-A | N-(piperidinyl-1-alkyl)-substituted cyclohexane carboxylic acid amides as 5-htia receptor antagonists | JOHN WYETH & BROTHER LIMITED (US) | 1998-06-09 | — | — | US | disclosed |
| EP-0711291-A1 | N-(PIPERIDINYL-1-ALKYL)-SUBSTITUTED CYCLOHEXANE CARBOXYLIC ACID AMIDES AS 5-HT1A RECEPTOR ANTAGONISTS | JOHN WYETH & BROTHER LIMITED (GB) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995002592-A1 | N-(PIPERIDINYL-1-ALKYL)-SUBSTITUTED CYCLOHEXANE CARBOXYLIC ACID AMIDES AS 5-HT1A RECEPTOR ANTAGONISTS | JOHN WYETH & BROTHER LTD. (GB) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | ADRB1 101/4885HTR1A 52/4885HTR2C 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.